Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nuvation Bio, Inc.

2.27
+0.02000.89%
Volume:2.15M
Turnover:4.84M
Market Cap:771.05M
PE:-1.07
High:2.29
Open:2.25
Low:2.20
Close:2.25
Loading ...

Nuvation Bio reports Q4 EPS (15c), two estimates (12c)

TIPRANKS
·
07 Mar

BRIEF-Nuvation Bio Q4 EPS USD -0.15

Reuters
·
07 Mar

Nuvation Bio Q4 Operating Expenses USD 55.437 Million

THOMSON REUTERS
·
07 Mar

Press Release: Nuvation Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Dow Jones
·
07 Mar

BRIEF-Nuvation Bio Enters Supply Agreement With Asymchem Laboratories

Reuters
·
06 Mar

Nuvation Bio Inc - Asymchem to Supply Taletrectinib to Nuvation Bio

THOMSON REUTERS
·
06 Mar

Nuvation Bio to Receive Up to $250 Million in Funding From Sagard Healthcare Partners

MT Newswires Live
·
03 Mar

RBC bullish on Nuvation as royalty deal, non-dilutive financings remove overhang

TIPRANKS
·
03 Mar

BRIEF-Nuvation Bio Secures Up To $250 Million In Non-Dilutive Financings From Sagard Healthcare Partners

Reuters
·
03 Mar

Nuvation Bio Inc: Proceeds From Royalty Interest Financing Expected to Fully Fund U.S. Commercial Launch of Taletrectinib

THOMSON REUTERS
·
03 Mar

Nuvation Bio Secures up to $250 Million in Non-Dilutive Financings From Sagard Healthcare Partners

THOMSON REUTERS
·
03 Mar

Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners

Business Wire
·
03 Mar

Nuvation Bio Starts Expanded Access Program for Lung Cancer Drug

MT Newswires Live
·
03 Feb

Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced Ros1-Positive Non-Small Cell Lung Cancer

THOMSON REUTERS
·
03 Feb

Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer

Business Wire
·
03 Feb

With 46% stake, Nuvation Bio Inc. (NYSE:NUVB) seems to have captured institutional investors' interest

Simply Wall St.
·
29 Jan

Nuvation Bio Inc : H.c. Wainwright Raises Target Price to $11 From $10

THOMSON REUTERS
·
23 Jan

Nuvation Bio Up Nearly 17%, on Track for Largest Percent Increase Since March 2024 -- Data Talk

Dow Jones
·
08 Jan

Nuvation Bio Price Target Raised to $10.00/Share From $6.00 by RBC Capital

Dow Jones
·
07 Jan

RBC Raises Price Target on Nuvation Bio to $10 From $6, Keeps Outperform, Speculative Risk

MT Newswires Live
·
07 Jan